显示原生EGF的外体增强了多克索鲁比的治疗效果,并降低了心脏毒性
Liang Mao1, Longtao Qian1, Xin Zhou1
1The Key Laboratory of Medical Electrophysiology of Ministry of Education, Medical Electrophysiological Key Laboratory of Sichuan Province, Collaborative Innovation Center for Prevention and Treatment of Cardiovascular Disease of Sichuan Province, Institute of Cardiovascular Research, Department of Cardiovascular Medicine, The First Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Journal of nanobiotechnology
|January 28, 2026
概括
携带多克索鲁比 (DOX) 的工程外体向表达表皮生长因子受体 (EGFR) 的瘤,增强抗瘤作用,同时最大限度地降低心脏毒性. 这种基于外体的新型药物递送系统显示出癌症治疗的前景.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 在瘤学瘤学.
背景情况:
- doxorubicin (DOX) 是一种强效的化疗药物,严重的心脏毒性限制了其使用.
- 目前用于减轻DOX心脏毒性的策略通常会降低其抗瘤有效性.
- 外体提供了一个针对药物输送的平台,有可能克服这些局限性.
研究的目的:
- 开发基于外体的纳米颗粒 (EGF-Exo-DOX) 用于向输送多克索鲁比 (DOX).
- 为了增强对EGFR表达瘤的抗瘤功效.
- 为了最大限度地减少DOX引起的心脏毒性.
主要方法:
- 基因工程A549细胞显示表皮生长因子 (EGF) 在外体.
- 带有DOX的装载工程外生体 (EGF-Exo).
- 评估了细胞吸收,瘤积累,抗瘤疗效和心脏毒性在体外和老鼠异种移植模型中.
主要成果:
- EGF-Exo证明了EGFR依赖的内部化和优选的瘤积累在心脏上.
- 与脂质体DOX相比,EGF-Exo-DOX在A549癌细胞中显示出增强的亡.
- 在体内研究显示,EGF-Exo-DOX显著降低了瘤负担和减轻了心脏毒性,没有观察到瘤效应.
结论:
- 带有表面EGF的工程外体可为EGFR过度表达的瘤提供有针对性的DOX输送.
- 与脂质体DOX相比,EGF-Exo-DOX的抗瘤功效优越,心脏毒性降低.
- 这种方法突出了工程外体的潜力,作为癌症治疗的新药输送平台.
相关概念视频
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
01:22Dose-Response Relationship: Potency and Efficacy
6.8K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.8K